Table 4.
Comparison of this study with previous studies of predictive models for recurrence-free survival of endometrial cancer patients.
| Obermair A | Bendifallah S | Ouldamer L | Wang J | |
|---|---|---|---|---|
| Number of cases | 2097 | 396 | 861 | 520 |
| Recurrence-free survival | 3-year | 3-year | 3-year | 3- and 5-year |
| Histologic type | I, II | I | I, II | I, II |
| FIGO stage | I–III | I–III | I–III | I–IV |
| Factors | ||||
| Age | Yes | Yes | Yes | — |
| Histological grade | Yes | Yes | — | Yes |
| FIGO stage | Yes | — | Yes | Yes |
| Histologic type | Yes | — | Yes | — |
| Tumor diameter ≥ 2 cm | — | Yes | — | Yes |
| Myometrial invasion ≥ 50 % | — | Yes | — | — |
| LVSI | Yes | Yes | Yes | — |
| Peritoneal washing | Yes | — | — | Yes |
| Surgical nodal staging | — | — | Yes | |
| Comparison with FIGO stage | — | — | — | Superior |
| 3-year internal validation | Yes (0.86) | Yes (0.74) | Yes (0.75) | Yes (0.89) |
| 5-year internal validation | — | — | — | Yes (0.87) |
| 3-year external validation | — | Yes (0.82) | — | Yes (0.88) |
| 5-year external validation | — | — | — | Yes (0.87) |
FIGO = International Federation of Gynecology and Obstetrics; LVSI = lymphovascular space involvement.